WO1999055847A3 - Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c - Google Patents

Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c Download PDF

Info

Publication number
WO1999055847A3
WO1999055847A3 PCT/US1999/009027 US9909027W WO9955847A3 WO 1999055847 A3 WO1999055847 A3 WO 1999055847A3 US 9909027 W US9909027 W US 9909027W WO 9955847 A3 WO9955847 A3 WO 9955847A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
replication
modulate
expressions
virus
Prior art date
Application number
PCT/US1999/009027
Other languages
English (en)
Other versions
WO1999055847A2 (fr
Inventor
Lawrence Blatt
James A Mcswiggen
Elisabeth Roberts
Pamela A Pavco
Dennis Macejak
Original Assignee
Ribozyme Pharm Inc
Lawrence Blatt
James A Mcswiggen
Elisabeth Roberts
Pamela A Pavco
Dennis Macejak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/274,553 external-priority patent/US20020082225A1/en
Application filed by Ribozyme Pharm Inc, Lawrence Blatt, James A Mcswiggen, Elisabeth Roberts, Pamela A Pavco, Dennis Macejak filed Critical Ribozyme Pharm Inc
Priority to CA002326695A priority Critical patent/CA2326695A1/fr
Priority to JP2000545991A priority patent/JP2002512791A/ja
Priority to EP99918837A priority patent/EP1075508A2/fr
Priority to AU36657/99A priority patent/AU757034B2/en
Priority to KR1020007011999A priority patent/KR20010043111A/ko
Publication of WO1999055847A2 publication Critical patent/WO1999055847A2/fr
Publication of WO1999055847A3 publication Critical patent/WO1999055847A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue

Abstract

L'invention se rapporte à des molécules d'acides nucléiques enzymatiques qui modulent l'expression et/ou la réplication du virus de l'hépatite C.
PCT/US1999/009027 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c WO1999055847A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002326695A CA2326695A1 (fr) 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c
JP2000545991A JP2002512791A (ja) 1998-04-27 1999-04-26 Ｃ型肝炎ウイルス感染に関連する疾患または状態の酵素的核酸治療
EP99918837A EP1075508A2 (fr) 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c
AU36657/99A AU757034B2 (en) 1998-04-27 1999-04-26 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
KR1020007011999A KR20010043111A (ko) 1998-04-27 1999-04-26 Ｃ형 간염 바이러스성 감염과 관련된 질환의 효소적 핵산치료제

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8321798P 1998-04-27 1998-04-27
US60/083,217 1998-04-27
US10084298P 1998-09-18 1998-09-18
US60/100,842 1998-09-18
US25760899A 1999-02-25 1999-02-25
US09/257,608 1999-02-25
US09/274,553 US20020082225A1 (en) 1999-03-23 1999-03-23 Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis c virus infection
US09/274,553 1999-03-23

Publications (2)

Publication Number Publication Date
WO1999055847A2 WO1999055847A2 (fr) 1999-11-04
WO1999055847A3 true WO1999055847A3 (fr) 2000-06-15

Family

ID=27491784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009027 WO1999055847A2 (fr) 1998-04-27 1999-04-26 Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c

Country Status (8)

Country Link
EP (1) EP1075508A2 (fr)
JP (1) JP2002512791A (fr)
KR (1) KR20010043111A (fr)
CN (1) CN1312856A (fr)
AU (1) AU757034B2 (fr)
CA (1) CA2326695A1 (fr)
ID (1) ID28053A (fr)
WO (1) WO1999055847A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
NZ546806A (en) * 2002-03-27 2007-03-30 Aegera Therapeutics Inc Antisense IAP nucleobase oligomers and uses thereof
KR100490699B1 (ko) * 2002-10-05 2005-05-19 제노프라 주식회사 씨형 간염 바이러스의 아이알이에스 발현 세포에서만 선택적으로 유전자 활성을 유도하는 트랜스-스플라이싱 리보자임
JP4866248B2 (ja) * 2004-01-23 2012-02-01 バイオメリュー・インコーポレイテッド 核酸増幅性能改良のための新規ヌクレオチド混合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019429A2 (fr) * 1994-01-13 1995-07-20 Ribozyme Pharmaceuticals, Inc. Procede et reactif permettant d'inhiber la replication du virus de l'hepatite c

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019429A2 (fr) * 1994-01-13 1995-07-20 Ribozyme Pharmaceuticals, Inc. Procede et reactif permettant d'inhiber la replication du virus de l'hepatite c

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOFFERSEN R E ET AL: "RIBOZYMES AS HUMAN THERAPEUTIC AGENTS", JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 38, no. 12, pages 2023-2037, XP002062054, ISSN: 0022-2623 *
ROBERTS, E. C. (1) ET AL: "Synthesis and testing of nuclease resistant hammerhead ribozymes directed against hepatitis C virus RNA.", HEPATOLOGY, (OCT., 1998) VOL. 28, NO. 4 PART 2, PP. 398A. MEETING INFO.: BIENNIAL SCIENTIFIC MEETING OF THE INT. ASS. FOR THE STUDY OF THE LIVER AND THE 49TH ANN. MEETING, NOV. 4-10, 1998. ISSN: 0270-9139., XP002127080 *

Also Published As

Publication number Publication date
AU3665799A (en) 1999-11-16
ID28053A (id) 2001-05-03
KR20010043111A (ko) 2001-05-25
JP2002512791A (ja) 2002-05-08
WO1999055847A2 (fr) 1999-11-04
CN1312856A (zh) 2001-09-12
AU757034B2 (en) 2003-01-30
CA2326695A1 (fr) 1999-11-04
EP1075508A2 (fr) 2001-02-14

Similar Documents

Publication Publication Date Title
AU8740398A (en) Amplification of nucleic acids
BR9510003A (pt) Moléculas de dna enzimático
EP1293565A3 (fr) Composante ARN de la télomérase de mammifères
WO1995019429A3 (fr) Procede et reactif permettant d'inhiber la replication du virus de l'hepatite c
AU5579699A (en) Rapid amperometric verification of pcr amplification of dna
AU9381598A (en) Method of amplifying dna and rna mismatch cleavage products
WO1996001614A3 (fr) Composant d'arn de la telomerase
AU3045699A (en) Amplification of nucleic acids
EP1135402A4 (fr) Modulation antisens de l'expression d'egr-1
WO1998032846A3 (fr) Traitement par acides nucleiques enzymatiques des maladies ou des etats lies aux niveaux de c-fos
WO1999055847A3 (fr) Traitement par acides nucleiques enzymatiques de maladies ou de troubles lies a une infection par le virus de l'hepatite c
WO2001064837A3 (fr) NETRINE β ET SES UTILISATIONS
AU4934099A (en) Method for enzymatic amplification of nucleic acid
ZA200101737B (en) Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof.
WO2000017346A3 (fr) Molecules hybridantes en epingle a cheveux servant a moduler l'expression genique
AU2180000A (en) Nucleic acid molecules of shrimp
AU3750899A (en) Nucleic acids and proteins of (c. elegans) insulin-like genes and uses thereof
WO1997008531A3 (fr) Detection de genotypes du virus gb de l'hepatite
AU3900095A (en) Amplification and detection of mycobacteria nucleic acids
AU2438501A (en) Expression of proteins from amplified, immobilized nucleic acids
DE69930862D1 (de) Expressionssysteme zur funktionellen expression von nukleinsäuren
AU3081495A (en) Nucleic acid amplification method using a modified nucleoside, and detection of the amplification product using antibodies
EP1288296A3 (fr) Procédé et réactif d'inhibition de la réplication virale de l'HBV
WO1998018818A3 (fr) Nouveaux inhibiteurs de l'hepatite b
AU5312699A (en) Novel mp-7 protein and nucleic acid molecules and uses therefor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99807262.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 36657/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999918837

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 545991

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2326695

Country of ref document: CA

Ref document number: 2326695

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007011999

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999918837

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007011999

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 36657/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020007011999

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999918837

Country of ref document: EP